NDA Reviews Will Be Risk-Based Under FDA Good Manufacturing Initiative
Executive Summary
The Center for Drug Evaluation & Research will apply a risk-based approach in considering manufacturing issues in reviewing NDAs, Office of Compliance Director David Horowitz said
You may also be interested in...
FDA Creates Four New Drug Chemistry Divisions For CMC Evaluation
FDA's restructuring of the Office of New Drug Chemistry includes the establishment of four new divisions to separate out pre- and post-marketing functions
GMP Oversight Will Have FDA-Wide Coordination Under Rx Quality Council
FDA's newly formed Council on Pharmaceutical Quality will oversee implementation of the agency's pharmaceutical current good manufacturing practices initiative for the 21st century
FDA Creates Four New Drug Chemistry Divisions For CMC Evaluation
FDA's restructuring of the Office of New Drug Chemistry includes the establishment of four new divisions to separate out pre- and post-marketing functions